In addition, FAM3A supplementation significantly lowered inflammatory markers such as IL1β, IL6, and TNFα both in plasma (Fig. 3e) and AAA tissues (Supplementary Fig. 2e) compared to the matched PBS group. This evidence concerns the gene IL1B and triple-A syndrome.